Evidence map›Paper›PMID 32082609›Full record

ArticlePilot and feasibility studies2020

Standard care informed by the result of a placental growth factor blood test versus standard care alone in women with reduced fetal movement at or after 36

Lindsay Armstrong-Buisseret, Peter J Godolphin, Lucy Bradshaw, Eleanor Mitchell, Sam Ratcliffe, Claire Storey, Alexander E P Heazell

Open access · goldAbstract read
In one paragraph

Article in Pilot and feasibility studies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Risk Factors for Adverse Pregnancy Outcomes in Reduced Fetal Movement: An IPD Meta-Analysis.BJOG : an international journal of obstetrics and gynaecology · 2025
    Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lindsay Armstrong-Buisseret1Nottingham Clinical Trials Unit (NCTU), Building 42, University of Nottingham, University Park, Nottingham, NG7 2RD UK.ORCID 0000-0002-8045-5464
Peter J Godolphin1Nottingham Clinical Trials Unit (NCTU), Building 42, University of Nottingham, University Park, Nottingham, NG7 2RD UK.
Lucy Bradshaw1Nottingham Clinical Trials Unit (NCTU), Building 42, University of Nottingham, University Park, Nottingham, NG7 2RD UK.
Eleanor Mitchell1Nottingham Clinical Trials Unit (NCTU), Building 42, University of Nottingham, University Park, Nottingham, NG7 2RD UK.
Sam Ratcliffe2Maternal and Fetal Health Research Centre, 5th Floor (Research), St Mary's Hospital, Oxford Road, Manchester, M13 9WL UK.
Claire Storey3International Stillbirth Alliance, c/o Maternal and Fetal Health Research Centre, 5th Floor (Research,), St Mary's Hospital, Oxford Road, Manchester, M13 9WL UK.
Alexander E P Heazell2Maternal and Fetal Health Research Centre, 5th Floor (Research), St Mary's Hospital, Oxford Road, Manchester, M13 9WL UK.
University of Nottingham · GBSt Mary's Hospital · GBManchester Academic Health Science Centre · GB

Funding

Department of Health CS-2013-13-009
6 · The paper itself

Abstract

backgroundBiomarkers of placental function can potentially aid the diagnosis and prediction of pregnancy complications. This randomised controlled pilot trial assessed whether for women with reduced fetal movement (RFM), intervention directed by the measurement of a placental biomarker in addition to standard care was feasible and improved pregnancy outcome compared with standard care alone.

methodsWomen aged 16-50 years presenting at eight UK maternity units with RFM between 36

resultsOverall, 2917 women presented with RFM ≥ 36 weeks, 352 were approached to participate and 216 (61%) were randomised (intervention

conclusionsA main trial using a placental biomarker in combination with delivery, as indicated by the biomarker, in women with RFM is feasible. The frequency of adverse outcomes in this population is low, hence, a large sample size would be required along with consideration of the most appropriate outcome measures.

trial registrationISRCTN, ISRCTN12067514; registered 8 September 2017.

Indexed as

Adverse pregnancy outcomeFeasibility studyPlacental biomarkerPlacental dysfunctionReduced fetal movementsFlt-1/PlGF ratio

Identifiers

PMID32082609
PMCPMC7020549
OpenAlexW3004440898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.